I am well aware of the predisposition to lung cancer from TB.
A search of p21 and cancer turns up 13,780 studies.

http://www.ncbi.nlm.nih.gov/m/pubmed/?term=p21+cancer
p53, cancer, 46,109 studies.

http://www.ncbi.nlm.nih.gov/m/pubmed/?term=p53%2C+cancer
ras, cancer, 22,709 studies.

http://www.ncbi.nlm.nih.gov/m/pubmed/?term=ras%2C+cancer
p21, lung cancer, 1,048 studies.

http://www.ncbi.nlm.nih.gov/m/pubmed/?term...%2C+lung+cancer
p53, lung cancer, 4,108 studies.

http://www.ncbi.nlm.nih.gov/m/pubmed/?term...%2C+lung+cancer
ras, lung cancer, 2,659 studies.

http://www.ncbi.nlm.nih.gov/m/pubmed/?term...%2C+lung+cancer
p21, SCLC, 35 studies.

http://www.ncbi.nlm.nih.gov/m/pubmed/?term=p21%2C+sclc
p53, SCLC, 148 studies.

http://www.ncbi.nlm.nih.gov/m/pubmed/?term=p53%2C+sclc
ras, SCLC, 73 studies.

http://www.ncbi.nlm.nih.gov/m/pubmed/?term=ras%2C+sclc
" p53 mutations are common in lung cancer and range from 33% in adenocarcinomas
to 70% in small cell lung cancers. "

http://p53.free.fr/Database/p53_cancer/p53_Lung.html
p53 accumulation in the organs of low-dose X-ray-irradiated mice.

http://www.ncbi.nlm.nih.gov/m/pubmed/8640750/
Occurrence of mutations in the epidermal growth factor receptor gene
in X-ray-induced rat lung tumors.

http://www.ncbi.nlm.nih.gov/m/pubmed/18271921
SCLC is actually a neuroendocrine cancer. In my American friend Bill's case,
there was some discussion of its hedgehog signalling pathway, and supplements
or herbs to inhibit it, in his thread at that time.

http://www.ncbi.nlm.nih.gov/m/pubmed/21983857
Here is a very lucky long-term survivor, party attributed to topotecan.

" Small cell lung cancer (SCLC) results in death within 1-2 months if left untreated. "
http://www.ncbi.nlm.nih.gov/m/pubmed/18787355/
In most patients however, resistance rapidly sets in after a typically initial good
response to chemotherapy, and the disease relapses in less than two months.

The newer chemo drugs have made hardly any difference to survival.

http://www.ncbi.nlm.nih.gov/m/pubmed/14512193

http://www.ncbi.nlm.nih.gov/m/pubmed/16488055/

http://www.ncbi.nlm.nih.gov/m/pubmed/21918390

http://www.ncbi.nlm.nih.gov/m/pubmed/17285598

http://www.ncbi.nlm.nih.gov/m/pubmed/20871263/

http://www.ncbi.nlm.nih.gov/m/pubmed/20559150
An exception might be the Japanese topoisomerase 2 inhibitor, amrubicin,
which I had urged Bill to get himself enrolled in a Phase 2 trial at that time.

However, his oncologist there turned a blind eye, despite the fact his hospital in Maine
was actually one of those involved in the trial at that time, and chose to treat
him with the 30-year old hopelessly outdated first-line regimen of cisplatin and
etoposide.

Amrubicin had already been used extensively in Japan for years before that.

http://www.ncbi.nlm.nih.gov/m/pubmed/17135647